Floatz logo

Rivastigmine

Apathy

University Hospital, LilleSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Apathy cohort.

Asset / SponsorPhaseRating
Methylphenidate
Sunnybrook Health Sciences Centre
Phase 4BBB
Tvp-1012
University Hospital, Clermont-Ferrand
Phase 4BB
FEOBV F-18
University Hospital, Bordeaux
Phase 3B
Modafinil
Brown University
Phase 3B
Rotigotine
University Hospital, Grenoble
Phase 3B

View all 13 →

Same molecule, other indications

Rivastigmine is also rated in:

cognitive disorderDormant
BBB
Indicative ·
73 / 100
View asset →
Alzheimer diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
cognitive disorderDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →